Gyroscope Merger Creates Gene Therapy Biotech For Eye Disorders
Executive Summary
A new UK/US biotech tie-up makes a company with the technology to deliver its gene therapies.
You may also be interested in...
Gyroscope Spins Forward With Dry AMD Gene Therapy
Fresh cash will help advance the UK firm's one-time investigational gene therapy for geographic atrophy and a listing in the US is in the offing.
BI Strengthens Research Efforts In IO Stromal Biology And Retinal Disease
Two preclinical antibodies targeted at stromal biology-associated immuno-oncology processes from Canada’s Northern Biologics have been acquired by Boehringer Ingelheim, which is also to collaborate with Switzerland’s CDR-Life on the development of a preclinical antibody fragment aimed at geographic atrophy associated with age-related macular degeneration.
Gyroscope Targeting ‘Huge’ Population With Dry AMD Gene Therapy
Bringing gene therapy to the masses: company raises extra £50m in series B fundraising for novel dry macular degeneration treatment